Search results for "antibodies"
Article
Optimizing Late-Stage and Commercial Cell-Culture Processes
In the early 1990s, cell titers for monoclonal antibodies (mAbs) were in the range of 50–100 mg/L, notes Dr. Andy Racher, associate director future technologies, Lonza Pharma & Biotech. Today, however…
Article
Challenges in Cell Harvesting Prompt Enhancements
Challenges in Cell Harvesting Prompt Enhancements
Higher cell titers and cell densities have posed a challenge to cell harvesting, a crucial step in biologics manufacturing.
By Feliza Mi…
Article
Automation Trend in Fill/Finish Reduces Contamination Risk
The company installed the new filling line to meet demand for innovative biologics, including vaccines, gene therapies, oncolytic live virus-based therapies, monoclonal antibodies, and recombinant pro…
Article
CDMOs Driving Emerging Bio/Pharma Success
…increased arsenal of weapons to aim at those targets with traditional small molecule and monoclonal antibodies being augmented by highly potent small molecules, antibody drug conjugates, and gene and…
Article
Capacity and Performance of a Next Generation Protein A Chromatography Resin
This application note demonstrates the binding capacity and purification performance of MabSelect PrismA in comparison with its predecessor products for both polyclonal and monoclonal antibodies. An i…
Article
Industry Adoption of Single-Use Systems Remains Low
Abzena, a CDMO, conducts development and GMP manufacture of antibody drug conjugates at its Bristol facility and conducts development and GMP manufacture of monoclonal antibodies and other recombinant…
Article
Exotoxin Clearance from mAb Samples in a Two-Step Chromatography Process
A heat-stable exotoxin can remain as a contaminant of a drug substance throughout the whole manufacturing process, with the risk of adversely affecting patients’ health. One such toxin is cereulide …
Article
Tools and Solutions for Separation of Charged mAb Variants
A biosimilar is an almost identical version of an originator product. To attain regulatory approval, a comparable quality to the reference product in terms of efficacy, purity, and safety should be …
Article
Platform Technologies Improve Protein Expression
“In the rapidly growing market of recombinant proteins and antibodies, our STEP technology provides a tool to complete preclinical phases at higher speed with reduced costs and with a higher success r…
Article
Development of Purification for Challenging Fc-Fusion Proteins
In response, titers for monoclonal antibodies (mAbs) and Fc-fusion proteins have significantly increased (1-5).
Particularly for Fc-fusion proteins, these improvements have resulted in a …